Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05609578 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 23, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Study sites: 166 to 94 · Primary completion date: Jun 1, 2026 to Sep 30, 2026v26 Show 2 more changesShow less
    • Study sites: 166 to 94
    • Primary completion date: Jun 1, 2026 to Sep 30, 2026
  2. Start date: Nov 30, 2022 to Nov 22, 2022 Study sites revised (166)v25 Show 1 more changeShow less
    • Study sites revised (166)

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites revised (166)v24 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (166)v23 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 125 to 166v22
Show 20 earlier versionsHide 20 earlier versions
  1. Start date: Nov 28, 2022 to Nov 30, 2022 Site contacts updated at 4 of 125 sitesv21 Show 1 more changeShow less
    • Site contacts updated at 4 of 125 sites
  2. Study sites: 55 to 125v20
  3. Re-verified, no change to tracked fieldsv19
  4. Start date: Jul 29, 2022 to Nov 28, 2022 Study sites: 53 to 55v18 Show 1 more changeShow less
    • Study sites: 53 to 55
  5. Study sites: 51 to 53v17
  6. Study sites: 48 to 51v16
  7. Study sites: 47 to 48v15
  8. Study sites: 41 to 47v14
  9. Study sites: 38 to 41v13
  10. Study sites: 34 to 38v12
  11. Study sites: 30 to 34v11
  12. Study sites: 25 to 30v10
  13. Study sites: 17 to 25v9
  14. Study sites: 14 to 17v8
  15. Study sites: 12 to 14v7
  16. Study sites: 8 to 12v6
  17. Eligibility criteria revisedv5 See this version in full on ClinicalTrials.gov ↗
  18. Primary completion date: Jun 23, 2025 to Jun 1, 2026 Primary endpoints: 1 to 2 · Study sites: 4 to 8 · Completion date: Dec 23, 2025 to Dec 1, 2026 · 4 morev4 Show 7 more changesShow less
    • Primary endpoints: 1 to 2
    • Study sites: 4 to 8
    • Completion date: Dec 23, 2025 to Dec 1, 2026
    • Interventions: Adagrasib in combination with pembrolizumab (Drug), Pembrolizumab (Biological) to Adagrasib oral dose of 400 mg twice daily tablets (Drug), Chemotherapy: Pemetrexed (Combination Product), Cisplatin/Carboplatin…
    • Eligibility criteria expanded, about 165 words
    • Secondary endpoints: 4 to 6
    • Study arms: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  19. Study sites: 3 to 4v3
  20. Study sites: 1 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Trial Details
NCT Number NCT05609578
Lead Sponsor Mirati Therapeutics Inc.
Conditions Advanced NSCLC, Metastatic Lung Cancer
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov